Hanmi wins gemicitabine patent
Published: 2007-04-23 06:56:00
Updated: 2007-04-23 06:56:00
Hanmi Pharm announced on April it acquired a Korean patent related to a core technology of producing gemcitabine intermediate, entitled 1--halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative and its manufacturing method.
Gemcitabine is used in various carcinomas: non-small cell lung cancer, pa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
